|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US6515117||ASTRAZENECA AB||C-aryl glucoside SGLT2 inhibitors and method|| |
(2 years from now)
|US7919598||ASTRAZENECA AB||Crystal structures of SGLT2 inhibitors and processes for preparing same|| |
(6 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8501698||ASTRAZENECA AB||Crystal structures of SGLT2 inhibitors and processes for preparing same|| |
(3 years from now)
|US8685934||ASTRAZENECA AB||Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof|| |
(6 years from now)
|US9616028||ASTRAZENECA AB||Bilayer tablet formulations|| |
(7 years from now)
Xigduo Xr is owned by Astrazeneca Ab.
Xigduo Xr contains Dapagliflozin; Metformin Hydrochloride.
Xigduo Xr has a total of 5 drug patents out of which 0 drug patents have expired.
Xigduo Xr was authorised for market use on 29 October, 2014.
Xigduo Xr is available in tablet, extended release;oral dosage forms.
Xigduo Xr can be used as treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone, treatment of type 2 diabetes mellitus.
The generics of Xigduo Xr are possible to be released after 12 November, 2030.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Indication (I)||Oct 18, 2022|
|M (M)||Feb 22, 2022|
Market Authorisation Date: 29 October, 2014
Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazo...
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic